Tag Archives: pharmaceuticals

by Sarah Brenner, MD, Jacob Mashiah, MD, Einat Tamir, MD, Ilan Goldberg, MD and Yonit Wohl, MD, Department of Dermatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel

Pemphigus is generally considered to stem from a genetic predisposition to the disease triggered and/or aggravated by one or more external factors. An acronym has been suggested from the name of the disease, PEMPHIGUS, to encompass those factors:

by Dr. David Rowe, DC, Dr. Nicholas Hall, DC

The following article is one in a series we are publishing about complementary medical approaches to living with pemphigus. These treatments are not meant to replace the therapies administered by your physician.

What is Chiropractic?

Chiropractic is a drugless healing art built on a very simple principle: the body is a self-healing, self-regulating organism that is under the complete control of the central nerve system. When vertebrae of the spine misalign and lose their ability to move freely in all directions, they often put pressure on the delicate nerves that carry vital nerve impulses from the brain to the body. This condition is called a Vertebral Subluxation Complex (VSC), and is the cause of many of the unwanted conditions that people suffer from every day. In fact, the damaging effects of VSC are further reaching than most people are aware of, and although chiropractic has come to be a mainstay for the treatment of headaches and musculoskeletal conditions such as low back pain and neck pain, the importance of us all maintaining a healthy spine has become more apparent as research continues to reveal the devastating effects of VSC on our health.

By Sergei A. Grando, MD, PhD, DSci
Professor of Dermatology
University of California Davis

The Need for Alternative Therapies for Pemphigus. In autoimmune pemphigus, systemic glucocorticosteroid treatment is life saving but may cause severe side effects. Pemphigus patients therefore need drugs that will provide safer treatment of their disease by replacing systemic use of glucocorticoid hormones such as Prednisone. Development of non-hormonal treatment is hampered by a lack of clear understanding of the mechanisms leading to pemphigus lesions. Pemphigus can be associated with myasthenia gravis, and in both diseases the autoantibodies to acetylcholine receptors are produced, suggesting a common mechanism of disease development.

By Grant J. Anhalt, M.D. and Hossein Nousari, M.D.
Johns Hopkins University, School of Medicine

In February 1997, the FDA approved a new drug, mycophenolate mofetil (MFM, also known as Cellcept) with an approved indication for use in immunosuppression of patients that have received renal transplants, to prevent graft rejection. MFM is actually a new variant of a drug that has been studied for about 20 years. The active metabolite, Mycophenolic acid (MPA) had been used in the past for the treatment of severe recalcitrant psoriasis.

Although MPA was shown to be a useful drug, it was withdrawn due to a high incidence of side effects, primarily infections such as herpes zoster ("shingles") and gastrointestinal side effects such as nausea and stomach discomfort. MFM is the reformulated product that does not have these same drawbacks, and has better bioavailability than MFA.